Pfizer and Ginkgo Bioworks Join Forces for $331M RNA Drug Development Deal
TL;DR
Pfizer and Ginkgo Bioworks have entered into an R&D deal to develop RNA drugs, focusing on three therapeutic programs. The deal includes potential milestone payments of up to $331 million, with an undisclosed upfront amount. This collaboration reflects the growing importance of therapeutics in Ginkgo's business.
Topics:businesspharmaceuticals#ginkgo-bioworks#pfizer#pharmaceuticals#randd-deal#rna-drugs#therapeutics
- Exclusive: Pfizer, Ginkgo sign R&D deal worth up to $331M to develop RNA drugs Endpoints News
- Ginkgo Bioworks Announces Multi-Target RNA Discovery Collaboration with Pfizer PR Newswire
- Pfizer hooks up with Ginkgo for $331M biobucks deal on unspecified targets FierceBiotech
- View Full Coverage on Google News
Want the full story? Read the original reporting
Read on Endpoints News